What is the purpose of this trial?
This is a prospective, multicenter, single-arm study in children 2 to 17 years of age with OI to evaluate efficacy and safety of denosumab.
Ages: 2 - 17 years
Dates: 09/29/2017 - 02/15/2018
Last Updated: 11/01/2017
Study HIC#: 1501015168